Study Analyzes Impact of Broad Claims in Myriad BRCA1 Patent, Suggests USPTO Errors
March 25, 2010
Study Analyzes Impact of Broad Claims in Myriad BRCA1 Patent, Suggests USPTO Errors
Researchers from Duke University analyzed a BRCA patent using bioinformatics and found that the USPTO may have erred in granting a particularly broad claim in the patent.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- Australia Federal Court Dismisses Cancer Patients' Challenge to Myriad's Gene Patent
February 15, 2013 / GenomeWeb Daily News - ACLU Files for Second Supreme Court Review of Myriad's Gene Patents
September 25, 2012 / GenomeWeb Daily News - UK's NICE Seeks Comments on Updated Guidelines for Familial Breast Cancer Genetic Testing, Treatment
January 23, 2013 / Pharmacogenomics Reporter - Analysts Provide Mixed Views on Myriad After Supreme Court Agrees to Rehear Patent Case
December 3, 2012 / GenomeWeb Daily News - Policy Experts Say Myriad's Proprietary Variant Database Sets Bad Precedent for Personalized Medicine
November 2, 2012 / Pharmacogenomics Reporter